Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 44.8%

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totalling 2,100,000 shares, an increase of 44.8% from the November 30th total of 1,450,000 shares. Approximately 2.5% of the company’s stock are short sold. Based on an average trading volume of 481,300 shares, the days-to-cover ratio is presently 4.4 days.

Analysts Set New Price Targets

A number of research firms recently weighed in on CMPX. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $5.00 to $4.00 in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Monday, November 11th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a report on Monday, September 16th. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, D. Boral Capital initiated coverage on shares of Compass Therapeutics in a report on Monday, December 23rd. They issued a “buy” rating and a $32.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.80.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Ground Swell Capital LLC purchased a new position in shares of Compass Therapeutics in the second quarter valued at $124,000. Barclays PLC boosted its stake in Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after purchasing an additional 112,614 shares during the period. Renaissance Technologies LLC grew its holdings in Compass Therapeutics by 99.7% during the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after buying an additional 70,200 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in shares of Compass Therapeutics during the second quarter valued at about $68,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Compass Therapeutics in the third quarter worth about $79,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Stock Down 0.3 %

CMPX traded down $0.01 during trading hours on Monday, hitting $1.46. The stock had a trading volume of 123,576 shares, compared to its average volume of 435,581. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.34. The company’s fifty day simple moving average is $1.60 and its 200 day simple moving average is $1.42. The stock has a market cap of $200.19 million, a PE ratio of -3.93 and a beta of 0.89.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. As a group, equities analysts expect that Compass Therapeutics will post -0.35 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.